MedPath

Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides

Phase 3
Terminated
Conditions
Lymphoma
Interventions
Drug: methoxypsoralen
Procedure: UV light therapy
Registration Number
NCT00056056
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Brief Summary

RATIONALE: Ultraviolet light therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. It is not yet known whether ultraviolet light therapy is more effective with or without bexarotene in treating mycosis fungoides.

PURPOSE: Randomized phase III trial to compare the effectiveness of ultraviolet light therapy using methoxsalen with or without bexarotene in treating patients who have mycosis fungoides.

Detailed Description

OBJECTIVES:

* Determine if ultraviolet A light therapy with methoxsalen (PUVA) with or without bexarotene yields a significantly higher overall response rate in patients with mycosis fungoides.

* Compare the overall response rate (CCR and partial response) in patients treated with these regimens.

* Compare the duration of CCR and time to relapse of patients treated with these regimens.

* Compare the number of PUVA sessions necessary to achieve a CCR in these patients.

* Determine the percentage of dropouts by patients treated with these regimens.

* Determine the safety of these regimens in these patients.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to participating center, age (60 and under vs over 60), and stage of disease (IB vs IIA). Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive PUVA comprising oral methoxsalen given 2 hours before whole body ultraviolet A therapy. PUVA is given 3 times per week.

* Arm II: Patients receive oral bexarotene once daily and PUVA as in arm I. In both arms, treatment repeats for up to 16 weeks in the absence of complete clinical response, disease progression, or unacceptable toxicity.

Patients are followed every 8 weeks until the first documented progression or relapse.

PROJECTED ACCRUAL: A total of 145 patients will be accrued for this study within 25 months.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
93
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Bexarotene and PUVAmethoxypsoralen-
Bexarotene and PUVAUV light therapy-
PUVAmethoxypsoralen-
PUVAUV light therapy-
Bexarotene and PUVAbexarotene-
Primary Outcome Measures
NameTimeMethod
Overall response rate (complete clinical response [CCR) and partial response [PR])35 months after first patient in
Secondary Outcome Measures
NameTimeMethod
Cumulative dose of UVA required to achieve CCR35 months after first patient in
Number of PUVA sessions necessary to achieve a CCR35 months after first patient in
Duration of CCR as measured by Logrank every 4 weeks during treatment and then every 8 weeks until progression35 months after first patient in
Time to relapse35 months after first patient in
Safety as assessed by CTC v2.0 every 4 weeks during treatment, then every 8 weeks35 months after first patient in
Percentage of dropouts as measured by the percentage of cases not completing treatment due to toxicity at the completion of treatment35 months after first patient in

Trial Locations

Locations (28)

CHR Hotel Dieu

🇫🇷

Nantes, France

Hospital Universitari de Bellvitge

🇪🇸

Barcelona, Spain

Allgemeines Krankenhaus - Universitatskliniken

🇦🇹

Vienna, Austria

U.Z. Gasthuisberg

🇧🇪

Leuven, Belgium

Centre Hospitalier Universitaire Henri Mondor

🇫🇷

Creteil, France

Klinikum der Stadt Mannheim

🇩🇪

Mannheim, Germany

Hospital Universitario Insular de Gran Canaria

🇩🇪

Tuebingen, Germany

Southwest German Cancer Center at Eberhard-Karls-University

🇩🇪

Tuebingen, Germany

Karl-Franzens-University Graz

🇦🇹

Graz, Austria

Ghent University

🇧🇪

Gent, Belgium

Bispebjerg Hospital

🇩🇰

Copenhagen, Denmark

Helsinki University Central Hospital

🇫🇮

Helsinki, Finland

Klinikum Minden

🇩🇪

Minden, Germany

Spedali Civili di Brescia

🇮🇹

Brescia, Italy

Semmelweis University

🇭🇺

Budapest, Hungary

Medizinische Klinik und Poliklinik II - Universitaetsklinikum Wuerzburg

🇩🇪

Wuerzburg, Germany

County Hospital

🇭🇺

Kaposvar, Hungary

Universita di Torino

🇮🇹

Turin, Italy

Rabin Medical Center - Beilinson Campus

🇮🇱

Petah-Tikva, Israel

Istituto Dermopatico Dell' Immacolata

🇮🇹

Rome, Italy

Leiden University Medical Center

🇳🇱

Leiden, Netherlands

Hospital de la Santa Cruz i Sant Pau

🇪🇸

Barcelona, Spain

Hospital Clinic de Barcelona

🇪🇸

Barcelona, Spain

UniversitaetsSpital Zuerich

🇨🇭

Zurich, Switzerland

St. Thomas' Hospital

🇬🇧

London, England, United Kingdom

Royal Infirmary of Edinburgh at Little France

🇬🇧

Edinburgh, Scotland, United Kingdom

Hospital Universitario Nuestra Senora de la Candelaria

🇪🇸

Santa Cruz de Tenerife, Spain

Hospital Universitario 12 de Octubre

🇪🇸

Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath